AMPHAmphastar Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $720M
- 1.7% YoY
- Operating margin
- 19.5%
- 31% YoY
- EBITDA
- $172M
- 26% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.2×
- $386M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear159% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear48% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $438M | $499M | $644M | $732M | $720M | 1.7% |
| Operating income | $70M | $107M | $197M | $205M | $140M | 32% |
| Net income | $62M | $91M | $138M | $160M | $98M | 39% |
| Operating cash flow | $98M | $89M | $184M | $213M | $156M | 27% |
| Capex | $27M | $24M | $38M | $41M | $35M | 15% |
| Stock-based comp | $19M | $18M | $20M | $24M | $27M | 12% |
| Buybacks | $29M | $40M | $58M | $85M | $76M | 12% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $343K · 2
- Net
- −$343K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $2M | 133 | 125 |
| FY2024 | $8M | −$8M | 185 | 93 |
| FY2023 | $8M | $29M | 308 | 94 |
| FY2022 | $7M | $13M | 139 | 90 |
| FY2021 | $7M | $9M | 116 | 100 |